Posted by Michael Wonder on 10 Dec 2023
Astellas' Veoza (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause
10 December 2023 - First in class treatment option reduces number and intensity of hot flashes and night sweats
Astellas today announced the European Commission on 7 December approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms associated with menopause.
